Panacea Biotec

Panacea Biotec

404.45
+1.35
(0.33%)
ann
Q1 Quarterly Results are out. Check out the updated financials1 day ago
Viewcross
right
Market Cap
2,477.29 Cr
EPS
-1.37
PE Ratio
-
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
581.90
52 Week Low
195.48
PB Ratio
2.96
Debt to Equity
0.02
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,640.70
#1 3,93,658.89
34.30
#1 54,729.00
9.71
#1 10,980
-19.84
47.35
6,115.50
1,62,347.31
69.37
9,712.00
18.67
2,191
26.74
35.29
1,596.20
1,28,926.32
23.86
28,409.50
7.12
5,291
9.88
66.07
3,656.90
1,23,766.11
61.13
11,539.40
6.99
1,911
19.91
59.05
2,601.20
1,07,359.00
56.78
12,744.20
#1 20.90
2,007
-18.14
60.15
1,275.20
1,06,424.51
#1 18.75
33,741.20
16.73
5,725
1.26
57.30
989.45
99,561.82
21.29
23,511.00
18.55
4,615
2.60
56.17
1,969.90
89,964.44
24.22
22,909.50
13.74
3,306
#1 51.64
53.40
32,745.00
69,580.84
47.71
6,684.70
9.64
1,414
11.55
44.46
5,464.00
65,330.32
28.51
13,458.30
3.70
2,216
21.39
70.65
Forecast
Actual
Growth Rate
Revenue Growth
14.35 %
Net Income Growth
-95.55 %
Cash Flow Change
99.98 %
ROE
-95.52 %
ROCE
-70.49 %
EBITDA Margin (Avg.)
-110.83 %

Quarterly Financial Results

Quarterly Financials
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
123
122
114
485
131
129
171
144
134
184
144
173
136
234
158
1,821
151
143
157
163
163
149
159
150
122
155
170
169
184
Expenses
116
179
87
258
104
149
132
150
111
144
127
167
134
226
144
171
191
109
124
135
140
147
151
143
130
140
156
159
168
EBITDA
7
-57
27
228
27
-20
39
-6
23
40
17
6
2
8
14
1,650
-40
34
33
29
24
2
8
8
-8
14
14
9
16
Operating Profit %
-17 %
-48 %
21 %
-110 %
17 %
-19 %
21 %
-19 %
16 %
21 %
11 %
1 %
-1 %
3 %
8 %
-21 %
-72 %
-4 %
-8 %
-4 %
-8 %
-2 %
-0 %
-4 %
-12 %
5 %
5 %
-20 %
-1 %
Depreciation
14
14
52
13
11
11
11
10
11
11
11
12
11
11
11
11
10
10
10
10
10
9
9
9
9
9
9
8
8
Interest
25
29
-14
26
41
42
47
45
45
48
46
47
48
50
52
31
1
1
1
1
1
1
1
1
1
1
1
1
1
Profit Before Tax
-33
-99
-11
189
-25
-73
-19
-61
-34
-19
-40
-53
-57
-53
-49
1,608
-51
23
22
18
13
-8
-2
-2
-17
5
4
0
7
Tax
3
-2
5
3
3
2
2
9
0
0
0
2
0
0
0
371
5
8
3
31
2
1
1
-0
-1
0
-0
2
3
Net Profit
-35
-97
-16
186
-28
-75
-21
-70
-34
-19
-40
-54
-57
-53
-49
1,238
-56
16
19
-13
11
-8
-2
-2
-16
5
4
-2
4
EPS in ₹
-5.75
-15.83
-2.60
30.35
-4.62
-12.25
-3.48
-11.38
-5.58
-3.16
-6.54
-8.84
-9.36
-8.65
-8.03
202.03
-9.17
2.56
3.16
-2.03
1.79
-1.35
-0.37
-0.23
-2.59
0.77
0.74
-0.31
0.66

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
1,931
1,854
1,800
1,608
1,376
1,390
1,178
1,759
1,271
1,241
1,290
Fixed Assets
1,144
1,071
1,001
949
806
657
609
622
600
582
695
Current Assets
526
549
533
560
508
683
511
951
562
485
545
Capital Work in Progress
156
161
30
40
23
24
34
17
42
102
94
Investments
5
4
7
7
5
6
0
5
14
40
214
Other Assets
626
619
761
611
542
703
534
1,115
615
517
0
Total Liabilities
1,931
1,854
1,800
1,608
1,376
1,390
1,178
1,759
1,271
1,241
1,290
Current Liabilities
706
475
588
691
938
452
449
776
330
309
367
Non Current Liabilities
750
930
846
611
90
743
960
109
101
94
92
Total Equity
475
450
366
306
347
196
-232
874
840
838
835
Reserve & Surplus
449
426
340
293
335
139
-257
849
816
814
829
Share Capital
22
22
6
6
6
6
6
6
6
6
6

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
-1
-10
-2
9
-2
26
12
-2
-11
7
Investing Activities
-37
17
-26
55
-6
-35
-48
1,283
430
10
Operating Activities
37
91
131
118
105
-31
107
-108
-423
-0
Financing Activities
-1
-117
-107
-164
-101
91
-47
-1,176
-18
-3

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.46 %
72.87 %
72.49 %
72.48 %
72.48 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.27 %
0.27 %
0.37 %
0.38 %
1.16 %
0.78 %
DIIs
1.27 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.29 %
0.43 %
0.43 %
0.54 %
0.00 %
0.00 %
0.84 %
1.07 %
1.16 %
1.17 %
1.49 %
1.52 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
17.34 %
15.21 %
15.57 %
15.99 %
15.14 %
15.60 %
15.79 %
15.97 %
15.82 %
16.15 %
19.20 %
19.63 %
19.90 %
20.42 %
18.11 %
18.98 %
18.45 %
18.17 %
Others
7.80 %
11.20 %
10.84 %
10.42 %
11.27 %
10.81 %
10.33 %
10.02 %
10.16 %
9.73 %
7.21 %
6.78 %
5.40 %
4.79 %
7.49 %
6.99 %
6.41 %
7.05 %
No of Share Holders
27,228
54,313
52,816
52,465
49,563
49,896
49,078
50,533
48,634
47,815
48,878
47,091
46,242
45,513
39,982
35,446
33,593
34,256

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
27 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
27 Sept 2024 332.95 273.05
12 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Nov 2024 349.80 349.80
13 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 Nov 2024 303.15 340.50
14 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Feb 2025 324.90 343.15
30 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
30 May 2025 528.95 520.90
14 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Aug 2025 400.65 430.65

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication5 days ago
Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter Ended 30.06.20257 days ago
Board Meeting Outcome for Outcome Of Board Meeting Held On August 14 20257 days ago
Demat Status Report For The Month Of July 2025Aug 07, 2025
Board Meeting Intimation for Approval Of Standalone And Consolidated Unaudited Financial Results (Provisional) For The Quarter Ended June 30 2025Aug 04, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJul 31, 2025
Intimation Under Regulation 30 And Regulation 31A(8) Of The Securities & Exchange Board Of India (Listing Obligations & Disclosure Requirements) Regulations 2015 - Approval For Reclassification Of Mrs. Sunanda Jain Mr. Sumit Jain And Ms. Radhika Jain FroJul 29, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 19, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 11, 2025
Intimation Of Settlement Of Disputes With Apotex Inc. Canada Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 09, 2025
Details Of Shares Dematerialised During June 2025 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations 2018Jul 07, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 07, 2025
Closure of Trading WindowJun 26, 2025
Details Of Shares Dematerialised During May 2025 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations 2018Jun 06, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 03, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 31, 2025
Intimation Regarding Appointment Of Secretarial AuditorMay 30, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2025
Standalone And Consolidated Audited Financial Results Along With Auditors Report For The Quarter And Financial Year Ended March 31 2025May 30, 2025
Board Meeting Outcome for 1. Standalone And Consolidated Audited Financial Results Along With Auditors Report For The Quarter And Financial Year Ended March 31 2025 2. Passing Over Of Dividend For The Financial Year 2024-25 3. Appointment Of SecretarMay 30, 2025
Board Meeting Intimation for For Approval Of The Audited Financial Results For The Quarter And Financial Year Ended March 31 2025 And Passing Over Of Dividend On Equity As Well As Preference Shares For The Said Financial Year.May 24, 2025
Nation-Wide Study Undertaken By Panacea Biotec Pharma Ltd. (Material WOS) Confirms Chilrun Full Accelerates Growth And Development In ChildrenMay 19, 2025
Details Of Shares Dematerialized During April 2025 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations 2018May 06, 2025
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 29, 2025
Receipt Of An Additional Award From UNICEF For Supply Of Bivalent Oral Polio Vaccine (Bopv) Worth ~US$ 5.20 Million In Q3 CY2025Apr 23, 2025
Details Of Shares Dematerialized During March 2025Apr 07, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 03, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementApr 01, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateApr 01, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 31, 2025
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotMar 31, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateMar 30, 2025
Closure of Trading WindowMar 26, 2025
Clarification On Movement In PriceMar 12, 2025
Clarification sought from Panacea Biotec LtdMar 11, 2025
Demat Report For The Month Of February 2025Mar 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 28, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 27, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 15, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateFeb 15, 2025
Integrated Filing (Financial)Feb 14, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 14, 2025
Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Nine Months Ended December 31 2024Feb 14, 2025
Board Meeting Outcome for 1. Unaudited Financial Results For The Quarter And Nine Months Ended 31.12.2024 2. Appointment / Re-Appointment Of Directors 3. Change In Senior Management Personnel 4. ReFeb 14, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 13, 2025
Demat Report For The Month Of January 2025Feb 07, 2025
Board Meeting Intimation for Approval Of Standalone And Consolidated Unaudited Financial Results (Provisional) For The Quarter And Nine Months Ended December 31 2024Jan 31, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI LODR Regulations)Jan 23, 2025
Details Of Shares Dematerialized During December 2024Jan 07, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 07, 2025

Technical Indicators

RSI(14)
Neutral
44.72
ATR(14)
Less Volatile
19.00
STOCH(9,6)
Neutral
56.87
STOCH RSI(14)
Neutral
47.01
MACD(12,26)
Bullish
0.28
ADX(14)
Weak Trend
14.65
UO(9)
Bearish
51.50
ROC(12)
Downtrend And Accelerating
-2.14
WillR(14)
Neutral
-61.36